Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIO NASDAQ:JSPR NASDAQ:MRKR NASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$1.55-4.9%$1.87$0.97▼$7.91$4.82M2.2328,589 shs1.22 million shsJSPRJasper Therapeutics$0.69-5.6%$0.61$0.32▼$3.25$20.41M3.073.22 million shs667,642 shsMRKRMarker Therapeutics$1.22-3.9%$1.41$0.81▼$2.46$21.18M1.4562,696 shs57,909 shsPLURPluri$1.78-0.8%$2.15$1.56▼$5.68$19.37M0.6447,618 shs9,360 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics-4.90%-9.88%-23.65%-14.84%-64.85%JSPRJasper Therapeutics-5.58%-22.21%+40.32%-17.89%-78.95%MRKRMarker Therapeutics-3.94%-6.87%-6.87%-12.86%-23.75%PLURPluri-2.73%-4.30%-13.63%-47.32%-67.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$1.55-4.9%$1.87$0.97▼$7.91$4.82M2.2328,589 shs1.22 million shsJSPRJasper Therapeutics$0.69-5.6%$0.61$0.32▼$3.25$20.41M3.073.22 million shs667,642 shsMRKRMarker Therapeutics$1.22-3.9%$1.41$0.81▼$2.46$21.18M1.4562,696 shs57,909 shsPLURPluri$1.78-0.8%$2.15$1.56▼$5.68$19.37M0.6447,618 shs9,360 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics-4.90%-9.88%-23.65%-14.84%-64.85%JSPRJasper Therapeutics-5.58%-22.21%+40.32%-17.89%-78.95%MRKRMarker Therapeutics-3.94%-6.87%-6.87%-12.86%-23.75%PLURPluri-2.73%-4.30%-13.63%-47.32%-67.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 1.00SellN/AN/AJSPRJasper Therapeutics 2.38Hold$12.001,643.17% UpsideMRKRMarker Therapeutics 2.25Hold$10.00719.67% UpsidePLURPluri 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CDIO, PLUR, JSPR, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/17/2026JSPRJasper Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/7/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/16/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026CDIOCardio Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/2/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/20/2026MRKRMarker Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026JSPRJasper Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetSector Perform$4.00 ➝ $3.005/15/2026JSPRJasper Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$10K458.80N/AN/A$3.82 per share0.41JSPRJasper TherapeuticsN/AN/AN/AN/A$0.15 per shareN/AMRKRMarker TherapeuticsN/AN/AN/AN/A$1.01 per shareN/APLURPluri$1.34M14.33N/AN/A($0.11) per share-16.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$6.50M-$3.38N/AN/AN/A-36,950.00%-78.82%-72.87%8/13/2026 (Estimated)JSPRJasper Therapeutics-$75.80M-$3.23N/AN/AN/AN/A-613.51%-162.52%8/12/2026 (Estimated)MRKRMarker Therapeutics-$12.16M-$0.61N/AN/AN/A-343.03%-73.29%-59.70%8/13/2026 (Estimated)PLURPluri-$22.58M-$4.53N/AN/AN/A-2,162.08%N/A-106.59%9/23/2026 (Estimated)Latest CDIO, PLUR, JSPR, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026MRKRMarker Therapeutics-$0.25N/AN/AN/A$0.68 millionN/A8/12/2026Q2 2026JSPRJasper Therapeutics-$0.38N/AN/AN/AN/AN/A5/15/2026Q1 2026CDIOCardio DiagnosticsN/A-$0.63N/A-$0.63N/AN/A5/15/2026Q1 2026MRKRMarker Therapeutics-$0.18-$0.16+$0.02-$0.16$0.78 million$0.75 million5/14/2026Q1 2026JSPRJasper Therapeutics-$0.46-$0.38+$0.08-$0.04N/AN/A5/14/2026Q3 2026PLURPluri-$0.66-$0.55+$0.11-$0.55$0.66 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A15.7715.77JSPRJasper TherapeuticsN/A2.262.26MRKRMarker TherapeuticsN/A4.794.79PLURPluriN/A0.330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%JSPRJasper Therapeutics79.85%MRKRMarker Therapeutics22.39%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics13.30%JSPRJasper Therapeutics2.30%MRKRMarker Therapeutics5.70%PLURPluri43.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics12.96 million2.57 millionNot OptionableJSPRJasper Therapeutics2028.00 million27.35 millionOptionableMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionablePLURPluri15010.79 million6.13 millionNo DataCDIO, PLUR, JSPR, and MRKR HeadlinesRecent News About These CompaniesPluri (NASDAQ:PLUR) Trading 3.3% Higher - Should You Buy?July 18, 2026 | americanbankingnews.comPluri in ongoing talks to extend EIB financingJuly 17, 2026 | theglobeandmail.comPluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%July 14, 2026 | markets.businessinsider.comPluri Receives Nasdaq Non-Compliance Notice, Faces Delisting RiskJuly 13, 2026 | tipranks.comLab-grown coffee and chocolate could save both industriesJune 26, 2026 | msn.comPluri Secures Insider Advance Subscription to Boost LiquidityJune 22, 2026 | tipranks.comPlurilock Announces Results of Annual General MeetingJune 16, 2026 | newsfilecorp.comNPluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products ListingJune 2, 2026 | globenewswire.comPluri in Good-Faith Talks on EIB Loan ResolutionJune 1, 2026 | tipranks.comPluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest InMay 31, 2026 | uk.finance.yahoo.comPluri Insider Ups Holding During YearMay 28, 2026 | finance.yahoo.comPluri Analyst Ratings and Price Targets | NASDAQ:PLUR | BenzingaMay 19, 2026 | benzinga.comNewcelX and Eledon Pharmaceuticals Collaborate on NCEL-101 for Type 1 Diabetes, Reporting Strong Financial Position and Strategic Growth PlansApril 30, 2026 | quiverquant.comQPluri Announces Financing Through Unregistered Equity Securities DealMarch 27, 2026 | tipranks.comPluri Inc.: Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finanznachrichten.dePluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private PlacementMarch 26, 2026 | finance.yahoo.comPluri Regains Nasdaq Compliance, Restoring Listing StabilityMarch 2, 2026 | tipranks.comPluri Biotech Secures China Patent for Immune Cell TechFebruary 18, 2026 | contractpharma.comCPluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. PatentFebruary 18, 2026 | markets.businessinsider.comPluri's cell therapy to extends lifespan and combat chronic diseaseFebruary 17, 2026 | i24news.tvINew MarketBeat Followers Over TimeMedia Sentiment Over TimeCDIO, PLUR, JSPR, and MRKR Company DescriptionsCardio Diagnostics NASDAQ:CDIO$1.55 -0.08 (-4.90%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.48 -0.07 (-4.52%) As of 07/24/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Jasper Therapeutics NASDAQ:JSPR$0.69 -0.04 (-5.58%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.70 +0.01 (+1.10%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Marker Therapeutics NASDAQ:MRKR$1.22 -0.05 (-3.94%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.22 0.00 (0.00%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Pluri NASDAQ:PLUR$1.78 -0.02 (-0.84%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 07/24/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
